0
Signin
countryflagUS

18889881171

AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%

Trevena Inc

Healthcare US TRVN

0.409USD
0.03(7.35%)

Last update at 2024-04-25T20:00:00Z

Day Range

0.370.42
LowHigh

52 Week Range

0.513.28
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -53.67000M -51.58800M -29.06900M -24.87100M -30.03900M
Minority interest - - - - -
Net income -53.66730M -51.16000M -29.36900M -28.05600M -30.78400M
Selling general administrative 34.73M 38.11M 19.25M 13.21M 18.98M
Selling and marketing expenses - 38.07M - - -
Gross profit -3.43600M -0.38700M 2.89M -0.07700M 5.73M
Reconciled depreciation 0.38M 0.43M 0.48M 0.56M 0.65M
Ebit -56.75700M -52.35300M -29.96200M -26.58000M -28.28900M
Ebitda -56.37500M -51.92500M -29.48500M -23.23800M -27.64400M
Depreciation and amortization 0.38M 0.43M 0.48M 3.34M 0.65M
Non operating income net other - - 0.44M 2.64M 2.69M
Operating income -56.37500M -51.92500M -29.48500M -26.58000M -30.49800M
Other operating expenses 55.96M 52.49M 32.55M 26.50M 34.80M
Interest expense 1.26M 0.00100M 0.03M 0.93M 2.23M
Tax provision - 0.00000M 0.30M 0.00000M 0.74M
Interest income 0.45M 0.16M 0.24M 0.42M 1.00M
Net interest income -0.80500M 0.16M 0.21M -0.51300M -1.23000M
Extraordinary items - - - - -
Non recurring - - - 0.11M 1.43M
Other items - - - - -
Income tax expense -0.00270M -0.42800M 0.30M 3.19M 0.74M
Total revenue -0.41800M 0.57M 3.07M 0.03M 5.73M
Total operating expenses 52.94M 51.54M 32.37M 26.50M 34.80M
Cost of revenue 3.02M 0.95M 0.18M 0.11M 0.00000M
Total other income expense net 2.71M 0.34M 0.42M 1.71M -0.96800M
Discontinued operations - - - - -
Net income from continuing ops -53.67000M -51.58800M -29.06900M -24.87100M -30.78400M
Net income applicable to common shares -53.67000M -51.58800M -29.36900M -24.87100M -30.78400M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 48.68M 80.12M 127.74M 46.99M 66.78M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.78M 1.45M 0.57M 1.68M 0.61M
Total liab 33.08M 15.49M 23.67M 16.92M 25.25M
Total stockholder equity 15.60M 64.63M 104.07M 30.08M 41.53M
Deferred long term liab - - - - 2.93M
Other current liab 5.46M 3.85M 9.00M 2.40M 3.51M
Common stock 0.00800M 0.17M 0.16M 0.09M 0.08M
Capital stock 0.00800M 0.17M 0.16M 0.09M 0.08M
Retained earnings -547.77200M -494.10200M -442.51400M -413.14500M -388.27400M
Other liab 5.48M - 0.00600M 0.00500M 2.93M
Good will - - - - -
Other assets 1.96M 2.85M 1.32M 1.33M 1.30M
Cash 38.32M 66.92M 109.40M 32.30M 32.89M
Cash and equivalents - - - - -
Total current liabilities 8.73M 9.19M 16.56M 9.11M 17.49M
Current deferred revenue - - 5.17M - -
Net debt -18.55500M -59.82200M -101.59900M -18.84400M -15.49900M
Short term debt 0.90M 0.79M 0.70M 5.66M 12.56M
Short long term debt - - - 5.04M 12.56M
Short long term debt total 19.77M 7.10M 7.80M 13.46M 17.39M
Other stockholder equity 563.36M 558.57M 546.42M 443.13M 429.73M
Property plant equipment 5.71M 6.55M 2.25M 2.71M 3.39M
Total current assets 41.01M 70.72M 119.04M 37.49M 62.09M
Long term investments - - - - -
Net tangible assets 15.60M 64.63M 104.07M 30.08M 41.53M
Short term investments - - - 3.50M 28.59M
Net receivables - 0.00000M 9.07M - -
Long term debt 13.43M - - - 4.81M
Inventory 0.91M 2.35M - - -
Accounts payable 2.37M 4.55M 1.69M 1.05M 1.42M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00100M - - -1.61800M -0.00900M
Additional paid in capital - - - - -
Common stock total equity - - 0.16M 0.09M 0.08M
Preferred stock total equity - - - - -
Retained earnings total equity - - -442.51400M -413.10000M -388.27400M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.96M 2.85M 1.32M 1.33M 1.30M
Deferred long term asset charges - - - - -
Non current assets total 7.67M 9.40M 8.70M 9.51M 4.69M
Capital lease obligations 6.33M 7.10M 7.80M 8.42M 0.02M
Long term debt total - - - 0.01M 4.83M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 0.02M -0.01600M 3.50M 25.58M 21.17M
Change to liabilities -0.67600M 1.53M 3.41M -1.25800M -1.16100M
Total cashflows from investing activities 0.02M -0.01600M 3.47M 25.58M 21.00M
Net borrowings 13.90M -0.00800M -5.04500M -12.66700M -12.67800M
Total cash from financing activities 23.50M 7.73M 95.02M -2.49700M 20.60M
Change to operating activities 0.45M -0.69500M -0.61000M -1.60400M 0.79M
Net income -53.67000M -51.58800M -29.36900M -24.87100M -30.78400M
Change in cash -27.95400M -42.47900M 77.10M -0.58100M 16.23M
Begin period cash flow 68.23M 110.71M 33.61M 34.20M 17.97M
End period cash flow 40.28M 68.23M 110.71M 33.61M 34.20M
Total cash from operating activities -51.47700M -50.19700M -21.39400M -23.66700M -25.37500M
Issuance of capital stock 9.64M 7.95M 101.01M 10.31M 33.20M
Depreciation 0.38M 0.43M 0.48M 0.56M 0.65M
Other cashflows from investing activities - - - 25.58M 21.17M
Dividends paid - - - - -
Change to inventory -0.62400M -2.35200M -3.41100M -2.35200M -2.35200M
Change to account receivables - -2.33700M 1.05M -1.12200M -1.12200M
Sale purchase of stock - - 101.15M 10.34M 33.28M
Other cashflows from financing activities 15.52M -0.20600M -0.93500M -0.13000M 0.08M
Change to netincome 2.66M 4.81M 3.29M 3.69M 5.32M
Capital expenditures 0.03M 0.02M 0.03M 0.03M 0.17M
Change receivables - - - - -
Cash flows other operating - - 0.79M -1.30300M 0.79M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - 77.10M -0.58100M 16.23M
Change in working capital -0.84900M -3.85100M 3.85M -2.86200M -0.37500M
Stock based compensation 3.68M 4.41M 3.28M 3.23M 4.37M
Other non cash items -1.01600M 0.41M 0.36M 0.63M 0.79M
Free cash flow -51.50500M -50.21300M -21.42100M -23.66700M -25.54400M

Fundamentals

  • Previous Close 0.38
  • Market Cap10.70M
  • Volume114782
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-34.15700M
  • Revenue TTM3.21M
  • Revenue Per Share TTM0.30
  • Gross Profit TTM -3.43600M
  • Diluted EPS TTM-2.64

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TRVN
Trevena Inc		 0.03 7.35% 0.41 - - 3.08 2.91 3.33 -0.3837
NVO
Novo Nordisk A/S		 -0.37 0.29% 125.79 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -3.3 2.60% 123.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.06 0.76% 397.70 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 0.06 0.07% 90.16 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

Trevena Inc

955 Chesterbrook Boulevard, Chesterbrook, PA, United States, 19087

Key Executives

Name Title Year Born
Ms. Carrie L. Bourdow Pres, CEO & Director 1963
Mr. Barry Shin Sr. VP & CFO 1972
Dr. Mark A. Demitrack Sr. VP & Chief Medical Officer 1958
Dr. Howard A. Rockman M.D. Scientific Founder, Consultant and Member of Scientific Advisory Board NA
Mr. Joel Solomon VP, Head of Legal, Chief Compliance Officer & Corp. Sec. NA
Mr. Michael Catalano VP of Marketing NA
Mr. Robert T. Yoder Sr. VP, Chief Bus. Officer & Head of Commercial Operations 1966
Ms. Patricia M. Drake Sr. VP & Chief Commercial Officer 1966

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).